Darolutamide in Spain: a multicenter review of real-world clinical practice in nmCRPC and mHSPC
Introduction Validating treatments outside clinical trials is crucial to confirm their routine value. Thus, this review examines Spanish real-world data (2022–2025) that show consistent effectiveness and good tolerability of darolutamide in both nmCRPC and mHSPC.Areas covered This structured narrative review summarizes Spanish real-world evidence on darolutamide reported between 2022 and 2025, based on abstracts and posters from national scientific meetings organized by SEOM, SEOR, AEU, GUO, and SEFH. The evidence comprises single-center case series, retrospective observational studies, and multicenter cohorts evaluating darolutamide in nmCRPC and mHSPC. Evidence from observational cohorts involved predominantly elderly patients with relevant comorbidity and frequent polypharmacy. In nmCRPC and mHSPC, biochemical responses were high and meaningful long-term outcomes were observed. Treatment was generally well tolerated, with low reported discontinuation rates. Available observational data do not establish a comparative reduction in drug–drug interactions.Expert opinion Emerging Spanish real-world evidence suggests that the clinical benefits observed with darolutamide in randomized trials may extend to older, medically complex patients with substantial polypharmacy. However, larger prospective studies with longer follow-up are needed to confirm long-term effectiveness, safety, and treatment persistence in routine clinical practice, alongside potential pharmacological advantages.
Authors
- Blanca Tavara Silva
- Joel Mases (ORCID: https://orcid.org/0000-0002-7991-7932)
- Sara Álvarez Rodríguez (ORCID: https://orcid.org/0000-0002-2337-3630)
- Oskar Estradé
- Antoni Vilaseca (ORCID: https://orcid.org/0000-0003-0160-620X)
- Fernando López‐Campos (ORCID: https://orcid.org/0000-0002-4077-0507)
- Pedro de Pablos‐Rodríguez (ORCID: https://orcid.org/0000-0003-2286-9893)
- Paola Usán Egea
- Jorge García Rodríguez (ORCID: https://orcid.org/0000-0001-9247-2803)
- Teresa Alonso Gordoa (ORCID: https://orcid.org/0000-0002-8966-7236)
- Enrique de la Peña
- Cristina Moretones Agut
- Ana Isabel Serrano Gutiérrez
- Luis A. San-José Manso
Institutions
- Hospital Universitario Fundación Alcorcón (ES)
- Fundación Instituto Valenciano de Oncología (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Universitario de La Princesa (ES)
- Hospital Universitario Central de Asturias (ES)
- Hospital de Cruces (ES)
- Hospital Universitario Lucus Augusti (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Hospital Universitario de Toledo (ES)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1080/14737140.2026.2762697
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00